← All trials
NCT05957081
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 28, 2023
- Primary completion
- Sep 10, 2025
- Completion date
- Oct 4, 2028
- First posted
- Jul 24, 2023
- Last posted
- Nov 18, 2023
- Enrollment
- 67
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PharmAbcineLead sponsor
- MerckCollaborator
- NovotechCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.